Colon

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 1:30pm

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.
  • The conference is taking place virtually from September 27 - 30, 2021.
  • Details for the presentation are as follows:
    Cantor Fitzgerald Virtual Global Healthcare Conference:
    Following the conference a webcast replay of the presentation will be available on the Investor section of the companys website, PDS Biotechnology .
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.

Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021

Wednesday, September 22, 2021 - 12:00pm

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Companys CEO Dr. Pnina Fishman will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021 and will join a panel discussion regarding medical cannabis.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Companys CEO Dr. Pnina Fishman will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021 and will join a panel discussion regarding medical cannabis.
  • The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19.
  • Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Stand Up To Cancer And Hip Hop Public Health Launch Colorectal Cancer Screening Education Initiative

Tuesday, September 21, 2021 - 2:30pm

Stand Up To Cancer, Hip Hop Public Health, Chuck D & Pete Colon collaborate on new colorectal cancer screening campaign.

Key Points: 
  • Stand Up To Cancer, Hip Hop Public Health, Chuck D & Pete Colon collaborate on new colorectal cancer screening campaign.
  • Chuck D, Hip Hop Public Health Advisory Board Member, and leader of the legendary hip-hop group Public Enemy, produced and recorded the English version of the PSA and hip-hop artist and Hip Hop Public Health ambassador Pete Colon recorded the Spanish-language version composed by multi-platinum producer Q.
  • "We are thankful to Chuck D and Pete Colon for lending their voices to this collaborative campaign with Hip Hop Public Health."
  • Hip Hop Public Health (HHPH) is an internationally recognized non-profit organization that creates and implements multimedia public health and education interventions designed to improve health literacy, inspire behavior change, and promote health equity.

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

Monday, September 20, 2021 - 1:30pm

The trial is being conducted in collaboration with Merck & Co.

Key Points: 
  • The trial is being conducted in collaboration with Merck & Co.
    VERSATILE-002 is studying two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread.
  • The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence regarding the safety of PDS0101.
  • There is an enormous unmet medical need for more effective treatment of advanced head and neck cancer.
  • That trial has enrolled patients with anal, cervical, head and neck, vaginal and vulvar cancer, who have failed prior treatment.

GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test

Monday, September 20, 2021 - 1:05pm

GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri, GRAILs groundbreaking multi-cancer early detection blood test.

Key Points: 
  • GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri, GRAILs groundbreaking multi-cancer early detection blood test.
  • With NYSDOH approval, Galleri is now available to residents in the state of New York by prescription to complement existing single cancer screening tests.
  • The standard set by New York State represents one of the most rigorous levels of validation required for laboratory developed tests.
  • The Galleri multi-cancer early detection test can detect more than 50 types of cancer through a routine blood draw.

Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

Friday, September 17, 2021 - 12:00pm

The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19.

Key Points: 
  • The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19.
  • In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing.
  • Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Thursday, September 16, 2021 - 3:17pm

VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied Sciences, in Germany. Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable. Barrett's is a gastrointestinal condition affecting around 150 million people globally. Terms of the transaction were not disclosed.

Key Points: 
  • Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable.
  • Satisfai Health's licensing of AI-enhanced software will provide clinicians with faster, more effective diagnostics during endoscopic procedures.
  • Diagnosis entails imaging and biopsies of the esophagus to check for precancerous cells (dysplasia) which can be treated to prevent esophageal cancer.
  • Satisfai Health is a leading medical solutions provider specializing in AI applications for gastroenterology.

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Thursday, September 16, 2021 - 3:17pm

VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied Sciences, in Germany. Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable. Barrett's is a gastrointestinal condition affecting around 150 million people globally. Terms of the transaction were not disclosed.

Key Points: 
  • Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable.
  • Satisfai Health's licensing of AI-enhanced software will provide clinicians with faster, more effective diagnostics during endoscopic procedures.
  • Diagnosis entails imaging and biopsies of the esophagus to check for precancerous cells (dysplasia) which can be treated to prevent esophageal cancer.
  • Satisfai Health is a leading medical solutions provider specializing in AI applications for gastroenterology.

MyTelemedicine Expands Remote Health Care Solutions with Roll-Out of Virtual Primary Care and Integrated Behavioral Health

Thursday, September 16, 2021 - 1:42pm

"Our new Virtual Primary Care services build on this foundation by letting users select a provider to be their primary care physician to monitor ongoing health concerns, order labs, medication management, as well as address preventative health care strategies," he says.

Key Points: 
  • "Our new Virtual Primary Care services build on this foundation by letting users select a provider to be their primary care physician to monitor ongoing health concerns, order labs, medication management, as well as address preventative health care strategies," he says.
  • In addition to virtual primary care, MyTelemedicine also is fighting back at the country's mounting mental health crisis with the expansion of its behavioral health services.
  • Both virtual primary care and expanded behavioral health services are aligned with MyTelemedicine's mission ofimproving healthcare access through user-friendly, member-focused technologies that connect patients with trusted health care providers anywhere in the country.
  • MyTelemedicine is a digital health care technology company that built around a full-stack HIPAA-compliant virtual care platform to let healthcare providers consult with patients remotely.

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Wednesday, September 15, 2021 - 1:30pm

Prior to joining PDS Biotech, Mr. Reid amassed more than 30 years of experience in the pharmaceutical industry, primarily in drug development.

Key Points: 
  • Prior to joining PDS Biotech, Mr. Reid amassed more than 30 years of experience in the pharmaceutical industry, primarily in drug development.
  • Greg brings a breadth of experience to PDS Biotech to support the advancement of the companys innovative pipeline, said PDS Biotech CEO, Frank Bedu-Addo.
  • An inducement grant of 63,800 shares of PDS Biotechs common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), was awarded as part of Mr. Reids compensation.
  • The awards were granted under PDS Biotechs 2019 Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4) and provides for the granting of equity awards to new employees of PDS Biotech.